DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was ...

Medical device company DexCom (NASDAQ:DXCM) in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company ...

25 analysts are following DexCom and have set target prices ranging from $82.0 to $110.0 per share. On average, they have ...

The medical instruments industry is currently undergoing a transformative phase, thanks to the rapid adoption of generative ...

DexCom Inc. closed 34.58% short of its 52-week high of $132.26, which the company reached on May 17th.

Shares of DexCom Inc. DXCM shed 1.11% to $84.11 Tuesday, on what proved to be an all-around mixed trading session for the ...

Dexcom (Nasdaq:DXCM) announced today that it promoted Jake Leach to the role of president, in addition to his post as COO.

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins. Check out why I am lowering my rating on DXCM from buy to hold.

Insulet beat first-quarter profit estimates on Thursday, buoyed by strong demand for its wearable insulin pumps, sending shares up 7% in extended trading.

Dexcom (NASDAQ:DXCM) announced today that it expanded its partnership with Oura, officially launching an integration with ...

After this recent quarterly performance and the resultant increase in stock price, an important question arises: is DXCM ...